<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management implications of a pathogenic or likely pathogenic variant in &lt;em&gt;BRCA1&lt;/em&gt; or &lt;em&gt;BRCA2&lt;/em&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management implications of a pathogenic or likely pathogenic variant in <em>BRCA1</em> or <em>BRCA2</em></h1>
<div class="graphic"><div class="figure"><div class="ttl">Management implications of a pathogenic or likely pathogenic variant in <em>BRCA1</em> or <em>BRCA2</em></div><div class="cntnt"><table cellspacing="0"><colgroup width="30%"></colgroup><colgroup width="70%"></colgroup> <tbody> <tr> <td class="subtitle1">Patient population</td> <td class="subtitle1">Intervention(s) that may be appropriate</td> </tr> <tr> <td class="subtitle2_left" colspan="2">Risk reduction</td> </tr> <tr> <td class="indent1">Women</td> <td> <ul> <li>Increased surveillance for breast cancer (clinical examination starting at age 25, mammography starting at age 30, MRI starting at age 25 to 29)</li> <li>Possible increased surveillance for gynecologic cancer (transvaginal ultrasound, CA-125)</li> <li>Risk-reducing bilateral mastectomy (shared decision-making)</li> <li>Recommendation for risk-reducing bilateral salpingo-oophorectomy after childbearing (age 35 to 40 for <em>BRCA1</em> carriers and 40 to 45 for <em>BRCA2</em> carriers), discussion of potential risks and benefits of hysterectomy</li> <li>Preconception counseling; some may opt for alternative reproductive technologies (donor gametes, IVF with PGT)</li> </ul> </td> </tr> <tr> <td class="indent1">Men</td> <td> <ul> <li>Increased surveillance for prostate cancer (screening starting at age 40 for <em>BRCA2</em> carriers, possible screening for <em>BRCA1</em> carriers)</li> <li>Preconception counseling; some may opt for alternative reproductive technologies (donor gametes, IVF with PGT)</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Family members</td> </tr> <tr> <td class="indent1">First- and second-degree relatives</td> <td> <ul> <li>Genetic testing for the familial variant in adult at-risk relatives</li> <li>Cascade testing of their relatives if appropriate</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="2">Cancer management</td> </tr> <tr> <td class="indent1">Breast cancer</td> <td> <ul> <li>Early-stage disease – Possible bilateral mastectomy for women</li> <li>Metastatic disease <ul> <li>Increased sensitivity to platinum-containing regimens</li> <li>Systemic therapy including a PARP inhibitor</li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1">Ovarian or other gynecologic cancer</td> <td> <ul> <li>Standard therapy based on tumor stage</li> <li>Bilateral salpingo-oophorectomy if early stage disease</li> <li>Increased sensitivity to platinum-containing regimens</li> <li>Systemic therapy including a PARP inhibitor</li> </ul> </td> </tr> <tr> <td class="indent1">Prostate cancer</td> <td> <ul> <li>Standard management based on PSA, stage, and grade</li> <li>Possible use of more aggressive therapy for low-risk disease</li> <li>Metastatic disease – Systemic therapy including a PARP inhibitor</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table is intended as an information summary and should not take the place of the clinical judgment of the treating specialists. Refer to UpToDate for additional information about genetic testing, screening, and management of individuals with hereditary breast and ovarian cancer syndromes.</div><div class="graphic_footnotes">MRI: magnetic resonance imaging; IVF: in vitro fertilization; PGT: preimplantation genetic testing; PARP: poly-ADP ribose polymerase; PSA: prostate-specific antigen.</div><div id="graphicVersion">Graphic 121904 Version 10.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
